Table 4

Cumulative survival parameter estimates with all patients with severe sepsis

Drotrecogin alfa


Cumulative survival

PROWESS

ADDRESS

Point estimate Pooled results (± SD)


28-day

75.3% [13]

81.5% [14]

79.4% (± 1.06)

Hospital discharge

70.3% [8]

79.4% [14]

76.4% (± 1.11)

3-month

66.1% [8]

NA

66.1% (± 1.86)

6-month

62.2% [8]

NA

62.2% (± 1.97)

12-month

58.9% [8]

NA

58.9% (± 2.05)

30-month

52.6% [8]

NA

52.6%(± 2.10)


Placebo


Cumulative survival

PROWESS

ADDRESS

Pooled results (± SD)


28-day

69.2% [13]

83% [14]

78.8% (± 1.04)

Hospital discharge

65.1% [8]

79.5% [14]

74.95% (± 1.12)

3-month

62.4% [8]

NA

62.4% (± 1.93)

6-month

60.3% [8]

NA

60.3% (± 1.98)

12-month

57.2% [8]

NA

57.2% (± 2.06)

30-month

49.3% [8]

NA

49.3% (± 2.10)


CI = confidence interval/NA = not available/SA = sensitivity analysis/SD = standard deviation

Costa and Brophy BMC Anesthesiology 2007 7:5   doi:10.1186/1471-2253-7-5

Open Data